Table 2.

Crude and overlap propensity score weighted odds ratios of dates of statin prescription for any brain tumor.

Characteristics	N of Brain Tumors	N of Controls	Odds Ratios for Any Brain Tumor (95% Confidence Interval)
	(Exposure/Total, %)	(Exposure/Total, %)	Crude	p-Value	Overlap Weighted Model †	p-Value
Dyslipidemia and Any statin prescription
Normal	1160/1893 (61.28)	4457/7572 (58.86)	1		1
Dyslipidemia without Statin	349/1893 (18.44)	1860/7572 (24.56)	0.72 (0.63–0.82)	<0.001 *	0.81 (0.73–0.90)	<0.001 *
Dyslipidemia with <365 days	184/1893 (9.72)	509/7572 (6.72)	1.39 (1.16–1.66)	<0.001 *	1.60 (1.36–1.87)	<0.001 *
Dyslipidemia with ≥365 days	200/1893 (10.57)	746/7572 (9.85)	1.03 (0.87–1.22)	0.731	1.22 (1.06–1.41)	0.007 *
Dyslipidemia and Lipophilic statin prescription
Normal	1160/1893 (61.28)	4457/7572 (58.86)	1		1
Dyslipidemia without Lipophilic statin	418/1893 (22.08)	2131/7572 (28.14)	0.75 (0.67–0.85)	<0.001 *	0.86 (0.77–0.95)	0.002 *
Dyslipidemia with <365 days	163/1893 (8.61)	461/7572 (6.09)	1.36 (1.12–1.64)	0.002 *	1.53 (1.30–1.81)	<0.001 *
Dyslipidemia with ≥365 days	152/1893 (8.03)	523/7572 (6.91)	1.12 (0.92–1.35)	0.259	1.28 (1.08–1.51)	0.003 *
Dyslipidemia and Hydrophilic statin prescription
Normal	1160/1893 (61.28)	4457/7572 (58.86)	1		1
Dyslipidemia without Hydrophilic statin	607/1893 (32.07)	2698/7572 (35.63)	0.86 (0.78–0.96)	0.009 *	0.96 (0.87–1.05)	0.384
Dyslipidemia with <365 days	85/1893 (4.49)	222/7572 (2.93)	1.47 (1.14–1.91)	0.003 *	1.64 (1.31–2.05)	<0.001 *
Dyslipidemia with ≥365 days	41/1893 (2.17)	195/7572 (2.58)	0.81 (0.57–1.14)	0.223	1.00 (0.77–1.32)	0.972

Abbreviations: CCI, Charlson Comorbidity Index; * Significance at p < 0.05. † Adjusted for age, sex, income, region of residence, diabetes history, CCI scores, and diabetes.